Fintel on MSN1d
Scotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform Recommendation
Fintel reports that on March 7, 2025, Scotiabank initiated coverage of ARS Pharmaceuticals (NasdaqGM:SPRY) with a Sector ...
California biotech company gets FDA approval for EpiPen alternative for kids
Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...
US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients (March 5)
Shares of the company were up 5.2% in extended trading. The spray, sold under the brand name neffy, will be dosed at 1 ...
US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients
The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...
ARS Pharmaceuticals initiated with an Outperform at Scotiabank
Scotiabank analyst Louise Chen initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $30 price target The firm says ...
Rocket Report: Starship fails for a second time; what’s to blame for Vulcan delays?
The Alpha rocket will launch Lockheed Martin’s LM 400 spacecraft from Vandenberg Space Force Base, with the 52-minute launch window opening at 6:25 am PT (14:25 UTC). Lockheed is self-funding the ...
Pharmabiz2d
US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms
US FDA approves ARS Pharma’s neffy 1 mg to treat type I allergic reactions for paediatric patients weighing 15 to less than 30 kilograms: San Diego Friday, March 7, 2025, 09:00 ...
Medical Marketing & Media2d
Rx Rundown: AbbVie, Jazz Pharmaceuticals, Sofinnova Partners and more
AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...
Managed Healthcare Executive3d
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 ...
PharmExec3d
FDA Approves ARS Pharmaceuticals’ neffy for Type 1 Allergic Reactions in Pediatric Patients
The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...
MPR3d
Neffy 1mg Approved to Treat Severe Allergic Reactions in Younger Children
The Food and Drug Administration (FDA) has approved neffy ® (epinephrine nasal spray) 1mg for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in pediatric patients aged 4 ...